Published: 2022-02-01
Lund, Sweden, 09:00 CET, 1 February 2022 - BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During January, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 35,850 due to the exercise of warrants.
As of 31 January 2022, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 65,490,522 shares, of which 64,200,522 are ordinary shares with one vote per share and 1,290,000 are series C-shares with one-tenth of a vote per share. The number of votes in the company amounts to 64,329,522 votes.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
The information in this press release is such that BONESUPPORT Holding AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CET on 31 January 2022.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT (https://bonesupport.com/en-eu/products/). The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com (https://bonesupport.com/en-eu/) for more information.
BONESUPPORT and CERAMENT are registered trademarks (https://bonesupport.com/en-eu/trademarks/) of BONESUPPORT AB.